QNCX Quince Therapeutics Inc
Price (delayed)
$1.32
Market cap
$58.08M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.31
Enterprise value
$66.59M
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence
Highlights
The debt has increased by 7% YoY but it has decreased by 4.1% QoQ
The net income has shrunk by 81% YoY and by 7% QoQ
The equity has shrunk by 65% YoY and by 33% QoQ
Key stats
What are the main financial stats of QNCX
Market
Valuations
Earnings
Shares outstanding
44M
Market cap
$58.08M
Enterprise value
$66.59M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.93
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$53.3M
Net income
-$56.83M
EBIT
-$56.74M
EBITDA
-$56.56M
Free cash flow
-$32.16M
Per share
Balance sheet
Liquidity
EPS
-$1.31
EPS diluted
-$1.31
Free cash flow per share
-$0.74
Book value per share
$0.69
Revenue per share
$0
TBVPS
$1.26
Total assets
$114.48M
Total liabilities
$84.33M
Debt
$14.72M
Equity
$30.15M
Working capital
$36.76M
Debt to equity
0.49
Current ratio
6.05
Quick ratio
5.6
Net debt/EBITDA
-0.15
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-42.5%
Return on equity
-115.8%
Return on invested capital
-88.6%
Return on capital employed
-52.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
QNCX stock price
How has the Quince Therapeutics stock price performed over time
Intraday
3.94%
1 week
-1.49%
1 month
-8.97%
1 year
25.71%
YTD
-29.41%
QTD
-0.75%
Financial performance
How have Quince Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$53.3M
Net income
-$56.83M
Gross margin
N/A
Net margin
N/A
The net income has shrunk by 81% YoY and by 7% QoQ
QNCX's operating income has dropped by 61% year-on-year and by 3.4% since the previous quarter
Growth
What is Quince Therapeutics's growth rate over time
Valuation
What is Quince Therapeutics stock price valuation
P/E
N/A
P/B
1.93
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has dropped by 56% year-on-year and by 6% since the previous quarter
The equity has shrunk by 65% YoY and by 33% QoQ
QNCX's P/B is 54% above its last 4 quarters average of 1.2 but 50% below its 5-year quarterly average of 3.7
Efficiency
How efficient is Quince Therapeutics business performance
The ROIC has dropped by 68% year-on-year and by 13% since the previous quarter
Quince Therapeutics's ROA has decreased by 48% YoY and by 17% from the previous quarter
The ROE has decreased by 37% QoQ
Dividends
What is QNCX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for QNCX.
Financial health
How did Quince Therapeutics financials performed over time
QNCX's total assets is 36% greater than its total liabilities
The current ratio has contracted by 37% from the previous quarter and by 25% YoY
The quick ratio has contracted by 37% from the previous quarter and by 29% YoY
The debt is 51% lower than the equity
The equity has shrunk by 65% YoY and by 33% QoQ
QNCX's debt to equity is up by 44% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.